Clovis Oncology Sell-Off May Be Overdone
Shares of Clovis Oncology Inc. (CLVS) were up 0.2% to $85 in after-hours trading on Monday, July 31, after finishing the trading session down 13.5%.
The Boulder, Colo.-based firm and Bristol-Myers Squibb Co. (BMY) before the market open unveiled a collaboration to evaluate the combination of Bristol-Myers' s immunotherapy Opdivo and Clovis Oncology's poly (ADP-ribose) polymerase (PARP) inhibitor Rubraca in Phase 3 studies in advanced advanced ovarian cancer and advanced triple-negative breast cancers.
The Boulder, Colo.-based firm and Bristol-Myers Squibb Co. (BMY) before the market open unveiled a collaboration to evaluate the combination of Bristol-Myers' s immunotherapy Opdivo and Clovis Oncology's poly (ADP-ribose) polymerase (PARP) inhibitor Rubraca in Phase 3 studies in advanced advanced ovarian cancer and advanced triple-negative breast cancers.